Resumen
Introducción: la resistencia a la insulina (RI) es un estado previo al desarrollo de diabetes tipo 2 (DT2) y es reversible con modificación en el estilo de vida. Sin embargo, este estado se encuentra subdiagnosticado por la dificultad en su medición.
Objetivo: evaluar el desempeño diagnóstico del cuestionario FINDRISC para identificar RI.
Material y métodos: se realizó un estudio transversal analítico en adultos de 20 a 60 años sin diagnóstico previo de DT2. Fueron excluidos quienes utilizaran esteroides y mujeres embarazadas. La RI fue diagnosticada mediante el índice triglicéridos/glucosa. Una curva ROC fue utilizada para establecer el punto de corte para el diagnóstico de RI. Se calculó sensibilidad, especificidad, valores predictivos y razones de verosimilitud. La medición del riesgo para RI se realizó con el instrumento FINDRISC.
Resultados: se incluyeron 253 participantes, con una prevalencia de RI de 60.8%. El área bajo la curva del instrumento FINDRISC fue de 0.813 (intervalo de confianza del 95% [IC 95%] 0.759-0.865), con un punto de corte de 8. La sensibilidad fue de 94.8%, con una especificidad de 48.5%, valor predictivo positivo de 74% y negativo de 86%, con una razón de verosimilitud positiva de 1.84 y una negativa de 0.11.
Conclusiones: el instrumento FINDRISC puede ser una herramienta útil para identificar a sujetos con resistencia a la insulina en el primer nivel de atención. Un puntaje ≥ 8 identifica a sujetos con RI.
Abstract
Background: Insulin resistance (IR) is a state prior to the development of type 2 diabetes (T2D) and it is reversible with lifestyle modification. However, it is underdiagnosed due to the difficulty in its measurement.
Objective: To evaluate the diagnostic performance of the FINDRISC questionnaire to identify IR.
Material and methods: An analytical cross-sectional study was performed in adults aged 20 to 60 years without previous diagnosis of T2D. Those using steroids and pregnant women were excluded. IR was diagnosed through the Triglycerides/glucose index. A ROC curve was used to establish the cut-off point for the diagnosis of IR. Sensitivity, specificity, predictive values and likelihood ratios were calculated. Risk measurement for IR was performed with the FINDRISC instrument.
Results: A total of 253 participants were included, with a prevalence of IR of 60.8%. The area under the curve of the FINDRISC instrument was 0.813 (95% confidence interval [95% CI] 0.759-0.865), with a cut-off point of 8. Sensitivity was 94.8% and specificity was 48.5%, positive predictive value was 74% and negative 86%, with a positive likelihood ratio of 1.84 and a negative of 0.11.
Conclusions: The FINDRISC instrument is a useful screening tool to identify subjects with IR at the first level of care. A score ≥ 8 identifies subjects with IR.
González Villalpando C. Dávila Cervantes CA. Zamora Macorra M. Trejo Valdivia B. González Villalpando ME. Risk factors associated to diabetes in Mexican population and phenotype of the individuals who will convert to diabetes. Salud Publica Mex. 2014;56(4):317-22.
Fragoso A, Mendes F, Silva AP, Neves PL. Insulin resistance as a predictor of cardiovascular morbidity and end-stage renal disease. J Diabetes Complications. 2015;39(8):1098-104.
Adeva-Andany MM, Martínez-Rodríguez J, González-Lucán M, Fernández-Fernández C, Castro-Quintela E. Insulin resistance is a cardiovascular risk factor in humans. Diabetes Metab Syndr. 2019;13(2):1449-55.
Park SY, Gautier JF, Chon S. Assessment of Insulin Secretion and Insulin Resistance in Human. Diabetes Metab J. 2021;45(5):641-54.
Espinel Bermúdez MC, Robles Cervantes JA, Villarreal Hernández LS, Villaseñor-Romero JP, Hernández-González SO, González-Ortiz M, et al. Insulin Resistance in adult primary care patients with a surrogate index, Guadalajara, México. 2012. J Investig Med. 2015;63(2):247-50. doi: 10.1097/ JIM.0000000000000130.
García-Alcalá H, Genestier-Tamborero CN, Hirales-Tamez O, Salinas-Palma J, Soto-Vega E. Frequency of diabetes, impaired fasting glucose, and glucose intolerance in high-risk groups identified by a FINDRISC survey in Puebla City, Mexico. Diabetes Metab Syndr Obes. 2012;5:403-6. doi: 10.2147/ DMSO.S35545.
Tuomilehto J, Lindström J, Eriksson JG, Valle TT, Hämäläinen H, Ilanne-Parikka P, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med. 2001; 344(18):1343-50.
Atayoglu AT, Inanc N, Başmisirli E, Çapar AG. Evaluation of the Finnish Diabetes Risk Score (FINDRISC) for diabetes screening in Kayseri, Turkey. Prim Care Diabetes. 2020;14 (5):488-93.
Makrilakis K, Liatis S, Grammatikou S, Perrea D, Stathi C, Tsiligros P, et al. Validation of the Finnish diabetes risk score (FINDRISC) questionnaire for screening for undiagnosed type 2 diabetes, dysglycaemia and the metabolic syndrome in Greece. Diabetes Metab. 2011;37(2):144-51.
Arellano Campos O, Gómez Velasco D, Bello Chavolla OY, Cruz Bautista I, Melgarejo Hernandez MA. Development and validation of a predictive model for incident type diabetes in middle-aged Mexican adults: the metabolic syndrome cohort. BMC Endocrine Disorders. 2019;19(41):1-10.
Lindström J, Tuomilehto J. The Diabetes Risk Score: A practical tool to predict type 2 diabetes risk. Diabetes Care. 2003; 26(3):725-31.
Carrillo-Larco RM, Aparcana-Granda DJ, Mejia JR, Barengo NC, Bernabe-Ortiz A. Risk scores for type 2 diabetes mellitus in Latin America: a systematic review of population-based studies. Diabet Med. 2019;36(12):1573-84.
Volaco A, Martins CM, Soares JQ, Cavalcanti AM, Moyses ST, Filho RP, et al. Neck Circumference and its Correlation to Other Anthropometric Parameters and Finnish Diabetes Risk Score (FINDRISC). Curr Diabetes Rev. 2018;14(5):464-71.
Draznin B, Aroda VR, Bakris G, Benson G, Brown FM, Freeman R, et al. Prevention or Delay of Type 2 Diabetes and Associated Comorbidities: Standards of Medical Care in Diabetes-2022. Diabetes Care. 2022;45(Suppl 1):S39-45.
Guerrero-Romero F, Simental-Mendía LE, González-Ortiz M, Martínez-Abundis E, Ramos-Zavala MG, Hernández-González SO, et al. The Product of Triglycerides and Glucose, a Simple Measure of Insulin Sensitivity. Comparison with the Euglycemic-Hyperinsulinemic Clamp. J Clin Endocrinol Metab. 2010;95(7):3347-51.
Avilés AGP, Rosas ERP, Bellot FT, Giles OA, Mendoza RD. Cuestionario FINDRISC FINnish Diabetes Risk Score para la detección de diabetes no diagnosticada y prediabetes. Archivos en Medicina Familiar. 2018;30(1):5-13.
Fizelova M, Jauhiainen R, Stančáková A, Kuusisto J, Laakso M. Finnish Diabetes Risk Score Is Associated with Impaired Insulin Secretion and Insulin Sensitivity, Drug-Treated Hypertension and Cardiovascular Disease: A Follow-Up Study of the METSIM Cohort. PLoS One. 2016;11(11):e0166584. doi: 10.1371/journal.pone.0166584.
Parcha V, Heindl B, Kalra R, Li P, Gower B, Arora G, et al. Insulin resistance and cardiometabolic risk profile among nondiabetic American young adults: insights from NHANES. J Clin Endocrinol Metab. 2022;107(1):e25-37.
Barbosa JB, dos Santos AM, Barbosa MM, Barbosa MM, de Carvalho CA, Fonseca PC, et al. Metabolic syndrome, insulin resistance and other cardiovascular risk factors in university students. Cien Saude Colet. 2016;21(4):1123-36.
Do HD, Lohsoonthorn V, Jiamjarasrangsi W, Lertmaharit S, Williams MA. Prevalence of insulin resistance and its relationship with cardiovascular disease risk factors among Thai adults over 35 years old. Diabetes Res Clin Pract. 2010;89 (3):303-8.
Brodovicz KG, Dekker JM, Rijkelijkhuizen JM, Rhodes T, Mari A, Alssema M, et al. The Finnish Diabetes Risk Score is associated with insulin resistance but not reduced β-cell function, by classical and model-based estimates. Diabet Med. 2011; 28(9):1078-81.
Li G, Zhang P, Wang J Gregg EW, Yang W, Gong Q, et al. The long-term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20 year follow-up study. Lancet. 2008;371:1783-9.
Knowler WC, Fowler SE, Hamman RF, Christophi CA, Hoffman HJ, Brenneman AT, et al.; Diabetes Prevention Program Research Group. 10-Year follow-up of diabetes incidence and weight loss in the diabetes prevention program outcomes study. Lancet. 2009;374:1677-86.
Haw JS, Galaviz KI, Straus AN, Kowalski AJ, Magee MJ, Weber MB, et al. Long-term sustainability of diabetes prevention approaches: a tematic review and meta-analysis of randomized Clinical trials. JAMA Intern Med. 2017;177(12):1808-17.
Pan XR, Li GW, Hu YH, Wang JX, Yang WY, An ZX, et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance: the Da Qing IGT and diabetes study. Diabetes Care. 1997;20(4):537-44. doi: 10.2337/ diacare.20.4.537.
Kitabchi AE, Temprosa M, Knowler WC, Kahn SE, Fowler SE, Haffner SM, et al; Diabetes Prevention Program Research Group. Diabetes Prevention Program Research Group. Role of insulin secretion and sensitivity in the evolution of type 2 diabetes in the diabetes prevention program: effects of lifestyle intervention and metformin. Diabetes. 2005;54(8):2404- 14. doi: 10.2337/diabetes.54.8.2404.
Yu X, Wang L, Zhang W, Ming J, Jia A, Xu S, et al. Fasting triglycerides and glucose index is more suitable for the identification of metabolically unhealthy individuals in the Chinese adult population: A nationwide study. J Diabetes Investig. 2019;10(4):1050-8.
Perreault L, Pan Q, Mather KJ, Watson KE, Hamman RF, Kahn SE, et al. Effect of regression from prediabetes to normal glucose regulation on long-term reduction in diabetes risk: results from the Diabetes Prevention Program Out-comes Study. Lancet. 2012;379(9833):2243-51.
Jurkovičová J, Hirošová K, Vondrová D, Samohýl M, Štefániková Z, Filová A, et al. The Prevalence of Insulin Resistance and the Associated Risk Factors in a Sample of 14-18-Year-Old Slovak Adolescents. Int J Environ Res Public Health. 2021:18(3):909.